Our Management
Team

Manfred
Rüdiger, PhD

Dr. Manfred Rüdiger has been Chief Executive Officer (CEO) of CatalYm since late 2017. He has more than 20 years of experience in executive functions in the international biotech industry…

Christine
Schuberth-Wagner,
PhD, MBA

Christine Schuberth-Wagner is Chief Scientific Officer (CSO) at CatalYm. She joined the company in November 2018 with more than 10 years of experience in drug discovery and …

Eugen
Leo,
MD-PhD, MBA

Eugen Leo is Chief Medical Officer (CMO) at CatalYm. Until late 2017, he served as CMO for Rigontec, a biotech company focused on the innate immune system …

Karen
Silence, PhD

Karen Silence is Senior Vice President, CMC, at CatalYm and brings more than 20 years of experience in antibody development, from pre-clinical research to Phase II clinical studies …

Anne
Burger, MBA

Anne Burger is Chief Financial Officer (CFO) at CatalYm and brings more than 15 years of experience in financial operations at biotech and medtech companies throughout Europe …

Board of
Directors

Daniela
Couto, PhD

Daniela Couto is a Principal at BioGeneration Ventures.

Daniela served as Managing Director of Staten Biotech, an antibody company in the cardiovascular space that is now collaborating with Novo Nordisk (€ 430 million potential deal). Previously, she was co-founder and CEO at Cell2B, a life sciences company dedicated to treating immune and inflammatory diseases.

Daniela holds a M.Sc. degree with honors in Biomedical Engineering from Universidade do Minho, Portugal and a PhD degree with the highest honors in Bioengineering from Instituto Superior Técnico (IST) – Technical University of Lisbon and the Massachusetts Institute of Technology (MIT-Portugal Program).

Hans
van Eenennaam, PhD

Dr. van Eenennaam currently serves as Chief Scientific Officer of AIMM Therapeutics. Up until March 2019, Dr. van Eenennaam served as Executive Vice President of Antibody Research and Site Head for Aduro Biotech Europe. In 2015, Aduro Inc. acquired BioNovion B.V., a company advancing novel antibody therapies for Immune Oncology, which van Eenennaam co-founded in 2011, and served on in the role of Chief Operational Officer.

At BioNovion, and later at Aduro he was involved in the discovery and development of three clinical, and one preclinical, stage antibodies: CD27, APRIL (BION-1301), CTLA-4 (ADU-1604) and SIRP (ADU-1806), respectively. Earlier in his career, he held numerous positions of increasing responsibility at Organon in Oss, Netherlands, and the Organon Research Center in Cambridge, Massachusetts, USA, which was acquired by Schering-Plough Corporation in 2007 and later by Merck & Co.

While at Organon, Dr. van Eenennaam and colleagues discovered pembrolizumab (Keytruda®). In 2016, he was awarded the Inventor of the Year Award from the Educational Foundation of the Intellectual Property Owner Association. Dr. van Eenennaam received his doctorate (cum laude) in autoimmune biochemistry from Radboud University in Nijmegen, Netherlands.

Holger
Reithinger, PhD

Holger is General Partner and heads the Munich office of Forbion. He is also a member of the investment committee for the High-Tech Gründerfonds, Germany’s biggest early-stage and seed investor. Holger has served on the Boards of numerous life sciences companies. Prior to joining Forbion, Holger was Partner at Global Life Science Ventures and Director at Germany’s healthcare practice of 3i and Investment Manager at Technologieholding VC.

Prior to his VC activities, Holger gained operational experience as a product development manager at Biometra/Whatman Plc, now part of GE Healthcare. He holds a PhD in Biochemistry from the Max-Planck-Institute of Biophysics in Frankfurt and studied Molecular Biology/Microbial Biology and Biochemistry at the University of Heidelberg and at the Ludwig-Maximilians-University in Munich, Germany.

Rogier
Rooswinkel, PhD

Rogier is Partner at Forbion, and responsible for evaluating and structuring new investment opportunities across all disease areas, with an emphasis on oncology and university spin-outs. Prior to joining Forbion in 2013, Rogier worked as a post-doc at the Netherlands Cancer Institute, Division of Immunology. Rogier holds a PhD degree from the University of Amsterdam, Netherlands, in the field of oncology.

Jörg
Wischhusen, PhD

Professor Wischhusen is scientific co-founder of CatalYm. He is also the Head of the Section of Experimental Tumor Immunology at the University of Würzburg Medical School, Germany. Prof. Wischhusen’s current research is directed towards tumor-host interactions in ovarian and breast cancer, with a strong focus on tumor-initiating cells and their ability to evade immunosurveillance.

Previously, he was a research group leader at the Interdisciplinary Center for Clinical Research in Würzburg. He received his PhD from the University of Tübingen, Germany in the field of molecular neuro-oncology.

Scientific &
Clinical Advisors

Reinhard
Dummer, MD

Professor Reinhard Dummer is Professor of the University of Zürich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland and is a key thought leader in worldwide cutaneous oncology. Currently, he is heading the Skin Cancer Unit and the Clinical Trial Unit of the Department of Dermatology. Prof. Dummer’s principal research interests are molecular biology, immunology and immunotherapy of cutaneous malignancies, including cutaneous lymphomas and melanomas and has published more than 741 scientific publications.

He is a founding and Board Member of the European Association of Dermato-Oncology (EADO), ESMO, URPP and a member of the German National Academy of Sciences (Leopoldina). Prof. Dummer is a past President of the European Society for Dermatological Research (ESDR) and the International Society for Cutaneous Lymphomas. Prof. Dummer began his medical education in hematology and oncology before successfully completing his dermatology residency in Würzburg, Germany, and Zürich, Switzerland.

Alexander
Eggermont, MD, PhD

Professor Alexander Eggermont is General Director of Gustave Roussy Cancer Institute, Professor of Oncology at the Paris-Sud University, and Professor of Oncological Surgery at the Erasmus University of Rotterdam in Holland. He also holds the Honorary Joseph Maisin Honorary Chair of Oncological Surgery at the Louvain Catholic University in Belgium, and an Honorary Doctorate at the University of Essen-Duisburg, Germany.

In addition, he is currently the President of the European Academy of Cancer Sciences, and the President of the Cancer Core Europe consortium. In 2015, Prof. Eggermont was elevated to the status of Chevalier of the Légion d’Honneur by the French Ministry of Foreign Affairs and International Development. His research specialty is in immunotherapy, the treatment of melanomas and sarcomas in addition to fundamental research in pathogenesis and immunology of tumors.

Wolf H.
Fridman, MD, PhD

Professor Wolf H. Fridman is Professor Emeritus of Immunology at the Paris Descartes University Medical School in Paris, France. He received his MD and PhD degrees from the University of Paris. He has been the founder and first Director of the Cordeliers Research Centre, a joint research structure between INSERM, University Paris Descartes, and University Pierre et Marie Curie.

He was also the Head of the Immunology Laboratory of European Hospital Georges Pompidou in Paris. Prof. Fridman’s current research is focused on the immune response in the tumor microenvironment to control clinical outcomes in cervical cancer. He is a world leader in the field of human tumor immunology and has authored over 480 scientific publications in the field.

Thomas
Gajewski, MD, PhD

Professor Thomas Gajewski is Professor in the Departments of Pathology and Medicine at the University of Chicago.  He oversees the melanoma oncology clinic and is Leader of the Immunology and Cancer Program at the University of Chicago Comprehensive Cancer Center. Prof. Gajewski is committed to investigating and developing new treatments for patients with melanoma, with a special interest in the development of immunotherapies, and is an author/co-author of over 270 scientific publications in the field.

He is an editor for Cancer Discovery, Journal for Experimental Medicine, and the Journal for Immunotherapy of Cancer, is on the Program Committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), and is past President of the Society for Immunotherapy of Cancer.

Jerome
Galon, MD, PhD

Professor Galon is Director of Research at INSERM (French National Institute of Health and Medical Research). He is also head of the INSERM Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center in Paris, France. He is Associate Director and co-founder of the European Academy of Tumor Immunology (EATI) and Board Director of the Society for Immunotherapy of Cancer (SITC, USA).

His research is focused on immuno-scoring and the tumor microenvironment. Dr. Galon has been awarded multiple prizes including the William B. Coley Award, USA, the Simone & Cino del Duca Cancer Research Award from the National Academy of Science, the Gallet & Breton Award from the National Academy of Medicine, the Rose Lamarca Award from the Medical Research Foundation. He received his PhD in Immunology from Jussieu University in Paris.

Ignacio
Melero, MD, PhD

Professor Melero is Professor of Immunology at the Clinic of the University of Navarra (CUN) and at the Center for Applied Medical Research (CIMA) of the University of Navarra, Pamplona, Spain. His current areas of research are focused on translational research with cell, gene and monoclonal antibody-mediated strategies for cancer immunotherapies.

Dr. Melero has been awarded the BIAL Prize of Medicine, the Conde de Cartagena Award from the Royal Academy of Medicine, Doctor Durantez LAIR Foundation Award and a Cancer Research Institute research award. He has served on the advisory boards of Bristol Myers-Squibb, Roche-Genentech, AstraZeneca, Merck Serono and Boehringer Ingelheim.

Michael J.
Overman, MD

Professor Michael Overman is Professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. He is a specialist in colorectal cancer and targeted therapy and has authored over 120 publications in the colorectal cancer field. He received his MD degree from the Johns Hopkins School of Medicine, USA.

Jörg
Wischhusen, PhD

Professor Wischhusen is scientific co-founder of CatalYm. He is also the Head of the Section of Experimental Tumor Immunology at the University of Würzburg Medical School, Germany. Prof. Wischhusen’s current research is directed towards tumor-host interactions in ovarian and breast cancer, with a strong focus on tumor-initiating cells and their ability to evade immunosurveillance.

Previously, he was a research group leader at the Interdisciplinary Center for Clinical Research in Würzburg. He received his PhD from the University of Tübingen, Germany in the field of molecular neuro-oncology.

We use cookies to improve your experience on our website. Find out more.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close